Cell and gene therapies have demonstrated their potential to transform medicine, but turning scientific breakthroughs into widely accessible treatments remains a formidable challenge. Complex manufacturing processes, fragmented data systems, demanding regulatory requirements, limited sites of care, and uncertain reimbursement models can all impede progress – but which represents the greatest bottleneck?
Produced by IBTV in collaboration with The Medicine Maker, experts from throughout the cell and gene therapy ecosystem make the case for where the industry should focus its efforts.
Moderated by Dalip Sethi of Terumo Blood and Cell Technologies, the discussion features Louis Cicchini of Cencora, Michael Baker of Fujifilm Biotechnologies, and Heather Purvis of Title21 Health Solutions. Together, they consider whether the sector is concentrating on the right problems, where greater collaboration is needed, and how AI and other emerging technologies could help remove the barriers between therapeutic innovation and patient access.
Watch the discussion below.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
